Cancer Res Treat.  2022 Apr;54(2):330-344. 10.4143/crt.2022.128.

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019

• Kang MJ
• Won YJ
• Lee JJ
• Jung KW
• Kim HJ
• Kong HJ
• Im JS
• Seo HG
• The Community of Population-Based Regional Cancer Registries

• KMID: 2528203
• DOI: http://doi.org/10.4143/crt.2022.128

Abstract

Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2019.
Materials and Methods
Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2019, with survival follow-up until December 31, 2020. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results
In 2019, newly diagnosed cancer cases and deaths from cancer were reported as 254,718 (ASR, 275.4 per 100,000) and 81,203 (ASR, 72.2 per 100,000), respectively. For the first time, lung cancer (n=29,960) became the most frequent cancer in Korea, excluding thyroid cancer. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.3% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. The incidence of thyroid cancer increased again from 2016 (annual percentage change, 6.2%). Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years (annual decrease of 2.7% from 2002 to 2013; 3.3% from 2013 to 2019). The 5-year relative survival between 2015 and 2019 was 70.7%, which contributed to prevalent cases reaching over 2 million in 2019.
Conclusion
Cancer survival rates have improved over the past decades, but the number of newly diagnosed cancers is still increasing, with some cancers showing only marginal improvement in survival outcomes. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics.

Keyword

Neoplasms; Incidence; Mortality; Survival; Prevalence; Korea

Figure

• 

  Fig. 1 The five common sites of cancer incidence by age group and sex for 2019 in Korea. (A) Men. (B) Women. Numbers in parentheses are age-specific incidence rates per 100,000. CNS, central nervous system.

• 

  Fig. 2 Age-specific incidence rates of common cancers for 2019 in Korea. (A) Men. (B) Women.

• 

  Fig. 3 Annual age-standardized cancer incidence and mortality rates by sex for all sites from 1983 to 2019 in Korea. Age standardization was based on Segi’s world standard population.

• 

  Fig. 4 Trends in age-standardized incidences of selected cancers by sex from 1999 to 2019 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population.

• 

  Fig. 5 Trends in age-standardized mortalities of selected cancers by sex from 1983 to 2019 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population. a)Cancers of cervix uteri, corpus uteri, and unspecified combined (C53–C55), due to their unclear classifications in the past.

• 

  Fig. 6 Five-year relative survival rates by stage at diagnosis and stage distribution of selected cancers by sex in Korea, 2015–2019. (A) Men. (B) Women. Staging according to the Surveillance, Epidemiology, and End Results stage categories. For each cancer type, stage categories do not total 100% because sufficient information was not available to stage all cases. a)Includes the gallbladder and other/unspecified parts of the biliary tract.

• 

  Fig. 7 Prevalent cases of common cancers by time since cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2020 among all cancer patients diagnosed between 1999 and 2019.

Reference

References

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2022 Feb 13]. Available from: https://gco.iarc.fr/today .

2. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021; 127:3029–30.

3. Statistics Korea [Internet]. Daejeon: Statistics Korea;2020. [cited 2022 Feb 13]. Available from: http://kosis.kr .

4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005; 37:325–31.

5. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi. 1998; 45:1011–7.

6. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed 1st rev. Geneva: World Health Organization;2013.

7. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization;1994.

8. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today – data and methods [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2022 Feb 13]. Available from: https://gco.iarc.fr/today/data-sources-methods .

9. Cancer incidence in five continents, XI Chapter 3 Classification and coding [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2022 Feb 13]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter3.aspx .

10. Young JL Jr, Roffers SD, Ries LA, Fritz AG, Hurlbut AA. SEER summary staging manual 2000: codes and coding instructions. National Cancer Institute NIH Pub No 01-4969. Bethesda, MD: National Cancer Institute;2001.

11. Cancer incidence in five continents, Vol XI Chapter 7 Age standardization [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2022 Feb 13]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter7.aspx .

12. Segi M. Cancer mortality for selected sites in 24 countries 1950–1957. Sendai: Tohoku University School of Medicine;1960.

13. Surveillance Research Program Joinpoint Regression Program, version 4801 [Internet]. Bethesda, MD: Surveillance Research Program, National Cancer Institute;2020. [cited 2022 Feb 13]. Available from: https://surveillance.cancer.gov/join-point/ .

14. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note, No 10. Bethesda, MD: National Cancer Institute;1959.

15. Paul Dickman [Internet]. Stockholm: PaulDickman.com;2016. [cited 2022 Feb 13]. Available from: http://www.pauldickman.com .